

0165

rjp.imm 2.46

15 July 1985

Dr R S Lane  
Blood Products Laboratory  
Dagger Lane  
Elstree  
Borehamwood  
HERTS  
WD6 3BX

Dear Richard

HEAT TREATED FVIII

We are now both involved in the clinical evaluation of our respective heat treated FVIII products. For our present product (68°/24 hr) we are primarily concerned with half-life and recovery since it is unlikely that we will achieve freedom from NANB.

However, since we anticipate future trials of a product subjected to more substantial conditions of viral inactivation, I believe it would be helpful if we exchanged our respective trial protocols with a view to achieving commonality wherever possible.

Accordingly, I am enclose a copy of our protocol.

With kind regards.

Yours sincerely

R J PERRY  
Director

Enc